Trazodone (HCl)

Trazodone (HCl) is oral antidepressant, unrelated to other known antidepressants. It possesses some similarities of action to other antidepressant drugs, however, and also has some action as an anxiolytic. Antidepressant activity is believed to be produced by blocking the reuptake of serotonin at the presynaptic neuronal membrane. Long-term therapy also can affect postsynaptic neuronal receptor binding sites. Trazodone is used in the treatment of major depression, generalized anxiety disorder, and insomnia. Trazodone was approved by the FDA in 1981.

Trazodone (HCl) is primarily indicated in conditions like Anxiety, Depression, Insomnia (Off-label), Aggressive behavior (Off-label), Cocaine and alcohol withdrawal (Off-label), Prevention of Migraine (Off-label).

Trazodone (HCl)

The severe or irreversible adverse effects of Trazodone (HCl), which give rise to further complications include Cardiac arrhythmias, Impotence, Bradycardia, Palpitation, Syncope. The signs and symptoms that are produced after the acute overdosage of Trazodone (HCl) include ECG alterations, Seizures, Respiratory arrest, Priapism. The symptomatic adverse reactions produced by Trazodone (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Drowsiness, Nasal congestion, Changes in libido, Increased intracranial pressure, Loss of memory, Incoordination.

Patients should observe caution while driving or performing other tasks requiring alertness, because it may produce drowsiness or blurred vision. Avoid concurrent administration with electricshock therapy. Discontinue the drug in patients whose white blood cells (W.B.Cs) count fall below the normal levels.

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

150 mg (150 (150)) 24 hourly PO — Increase dose to 300 mg after 1 week.

Safety not Established ( ) —

Safety not Established ( ) —

Trazodone (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholApraclonidine (HCl)Buspirone (HCl)Clonidine (HCl)DigoxinFosphenytoinGuanethidinePhenelzinePhenytoin (Na)Thioridazine (HCl)Coadministration of thioridazine and trazodone produce additive hypotensive effects by blockin alpha-1 adrenergic receptors.ModerateInitial dose should kept lower.Closely monitor the patient for adverse effects such as hypotension and tachycardia.Trifluoperazine (HCl)Trazodone and trifluoperazine both are alpha-1-adrenergic blockers and produces the additive hypotensive effect. Beside additive effects, competitive inhibition of metabolism may occur. ModerateClosely monitor for adverse effects such as hypotension and tachycardia. Initial dose should be lower.VORICONAZOLEVoriconazole may increase the serum concentration of trazodone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects Vortioxetineincreases the toxicity of vortioxetineuse alternative These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Tab Store Below 40°C. Protect from Sunlight and Moisture.